Business
Repligen to Buy BioLife Solutions for $1.5B, Deepening the Cell-Therapy Supply Chain
Adding BioLife’s cell-preservation technology to its bioprocessing tools, Repligen is betting on vertical integration as cell and gene therapies scale up.